相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A proof of concept for structure-based vaccine design targeting RSV in humans
Michelle C. Crank et al.
SCIENCE (2019)
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch et al.
LANCET (2018)
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
Joseph B. Domachowske et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study
Jacqueline U. McDonald et al.
VACCINE (2018)
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Judith Falloon et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
Allison August et al.
VACCINE (2017)
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Louis Fries et al.
IMMUNITY & AGEING (2017)
Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997-2012
Susan T. Pastula et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
Judith Falloon et al.
CLINICAL AND VACCINE IMMUNOLOGY (2017)
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
Gregory M. Glenn et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention
Lindsey R. Baden et al.
ANNALS OF INTERNAL MEDICINE (2016)
Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial
Iain D. Milligan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant
Judith Falloon et al.
VACCINE (2016)
Novel antigens for RSV vaccines
Barney S. Graham et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Joan O. Ngwuta et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Anders Krarup et al.
NATURE COMMUNICATIONS (2015)
Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
William Wold et al.
CURRENT GENE THERAPY (2014)
Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein
Anu Cherukuri et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)
Lindsey R. Baden et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
Jason S. McLellan et al.
SCIENCE (2013)
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
L. J. Anderson et al.
VACCINE (2013)
Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach
Nathaniel D. Lambert et al.
EXPERT REVIEW OF VACCINES (2012)
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Margarita Magro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years
Peter L. Collins et al.
VIRUS RESEARCH (2011)
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines - Nonadjuvanted vaccine or vaccine adjuvanted with alum - Given concomitantly with influenza vaccine to high-risk elderly individuals
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods
D. M. Fleming et al.
EPIDEMIOLOGY AND INFECTION (2007)
Respiratory syncytial virus infection in elderly and high-risk adults
AR Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults
EE Walsh et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women
FM Munoz et al.
VACCINE (2003)
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies
PA Piedra et al.
VACCINE (2003)
Mortality associated with influenza and respiratory syncytial virus in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors
MC Sprangers et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
分享论文
